MovDisordV3, PascalFrancis, Corpus, bibRecord, 000F22

Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease

Identifieur interne : 000F22 ( PascalFrancis/Corpus ); précédent : 000F21; suivant : 000F23

Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease

Auteurs : Nir Giladi ; Joseph Tal ; Tali Azulay ; Oliver Rascol ; David J. Brooks ; Eldad Melamed ; Wolfgang Oertel ; Werner H. Poewe ; Fabrizio Stocchi ; Eduardo Tolosa

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0218140

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Validation, Congélation, Questionnaire, Homme, Rasagiline.

English descriptors

KwdEn :
- Freezing, Human, Nervous system diseases, Parkinson disease, Questionnaire, Rasagiline, Validation.

Abstract

To revalidate the Freezing of Gait Questionnaire (FOG-Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG-Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ-39). FOG-Q dimensionality, test-retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG-Q with UPDRS, BDI, and PDQ-39. Comparisons between FOG-Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG-Q measures a single dimension. Test-retest reliability and internal reliability of FOG-Q score was high. FOG-Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG-Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as "Freezers" using FOG-Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG-Q was a reliable tool for the assessment of treatment intervention. FOG-Q item 3 was effective as a screening question for the presence of FOG.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease`
A11	`01`	`1`		`@1 GILADI (Nir)`
A11	`02`	`1`		`@1 TAL (Joseph)`
A11	`03`	`1`		`@1 AZULAY (Tali)`
A11	`04`	`1`		`@1 RASCOL (Oliver)`
A11	`05`	`1`		`@1 BROOKS (David J.)`
A11	`06`	`1`		`@1 MELAMED (Eldad)`
A11	`07`	`1`		`@1 OERTEL (Wolfgang)`
A11	`08`	`1`		`@1 POEWE (Werner H.)`
A11	`09`	`1`		`@1 STOCCHI (Fabrizio)`
A11	`10`	`1`		`@1 TOLOSA (Eduardo)`
A14	`01`			`@1 Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University @2 Tel-Aviv @3 ISR @Z 1 aut.`
A14	`02`			`@1 TechnoStat Ltd @2 Hod Hasharon @3 ISR @Z 2 aut. @Z 3 aut.`
A14	`03`			`@1 Service de Pharmacologie Medicale et Clinique, Faculté de Médecine @2 Toulouse @3 FRA @Z 4 aut.`
A14	`04`			`@1 Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital @2 London @3 GBR @Z 5 aut.`
A14	`05`			`@1 Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel-Aviv University @2 Tel-Aviv @3 ISR @Z 6 aut.`
A14	`06`			`@1 Centre of Nervous Diseases, Philipps-University of Marburg @2 Marburg @3 DEU @Z 7 aut.`
A14	`07`			`@1 Department of Neurology, University of Innsbruck @2 Innsbruck @3 AUT @Z 8 aut.`
A14	`08`			`@1 Department of Neuroscience and Neuromed, University La Sapienza @2 Rome @3 ITA @Z 9 aut.`
A14	`09`			`@1 Neurology Department, Hospital Clinic @2 Barcelona @3 ESP @Z 10 aut.`
A20				`@1 655-661`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000186090170030`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 24 ref.`
A47	`01`	`1`		`@0 09-0218140`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 To revalidate the Freezing of Gait Questionnaire (FOG-Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG-Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ-39). FOG-Q dimensionality, test-retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG-Q with UPDRS, BDI, and PDQ-39. Comparisons between FOG-Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG-Q measures a single dimension. Test-retest reliability and internal reliability of FOG-Q score was high. FOG-Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG-Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as "Freezers" using FOG-Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG-Q was a reliable tool for the assessment of treatment intervention. FOG-Q item 3 was effective as a screening question for the presence of FOG.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Validation @5 09`
C03	`03`	`X`	`ENG`	`@0 Validation @5 09`
C03	`03`	`X`	`SPA`	`@0 Validación @5 09`
C03	`04`	`X`	`FRE`	`@0 Congélation @5 10`
C03	`04`	`X`	`ENG`	`@0 Freezing @5 10`
C03	`04`	`X`	`SPA`	`@0 Congelación @5 10`
C03	`05`	`X`	`FRE`	`@0 Questionnaire @5 11`
C03	`05`	`X`	`ENG`	`@0 Questionnaire @5 11`
C03	`05`	`X`	`SPA`	`@0 Cuestionario @5 11`
C03	`06`	`X`	`FRE`	`@0 Homme @5 12`
C03	`06`	`X`	`ENG`	`@0 Human @5 12`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 12`
C03	`07`	`X`	`FRE`	`@0 Rasagiline @2 NK @2 FR @5 13`
C03	`07`	`X`	`ENG`	`@0 Rasagiline @2 NK @2 FR @5 13`
C03	`07`	`X`	`SPA`	`@0 Rasagilina @2 NK @2 FR @5 13`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 159`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0218140 INIST
ET :	Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease
AU :	GILADI (Nir); TAL (Joseph); AZULAY (Tali); RASCOL (Oliver); BROOKS (David J.); MELAMED (Eldad); OERTEL (Wolfgang); POEWE (Werner H.); STOCCHI (Fabrizio); TOLOSA (Eduardo)
AF :	Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University/Tel-Aviv/Israël (1 aut.); TechnoStat Ltd/Hod Hasharon/Israël (2 aut., 3 aut.); Service de Pharmacologie Medicale et Clinique, Faculté de Médecine/Toulouse/France (4 aut.); Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital/London/Royaume-Uni (5 aut.); Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel-Aviv University/Tel-Aviv/Israël (6 aut.); Centre of Nervous Diseases, Philipps-University of Marburg/Marburg/Allemagne (7 aut.); Department of Neurology, University of Innsbruck/Innsbruck/Autriche (8 aut.); Department of Neuroscience and Neuromed, University La Sapienza/Rome/Italie (9 aut.); Neurology Department, Hospital Clinic/Barcelona/Espagne (10 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 5; Pp. 655-661; Bibl. 24 ref.
LA :	Anglais
EA :	To revalidate the Freezing of Gait Questionnaire (FOG-Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG-Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ-39). FOG-Q dimensionality, test-retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG-Q with UPDRS, BDI, and PDQ-39. Comparisons between FOG-Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG-Q measures a single dimension. Test-retest reliability and internal reliability of FOG-Q score was high. FOG-Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG-Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as "Freezers" using FOG-Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG-Q was a reliable tool for the assessment of treatment intervention. FOG-Q item 3 was effective as a screening question for the presence of FOG.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Validation; Congélation; Questionnaire; Homme; Rasagiline
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Validation; Freezing; Questionnaire; Human; Rasagiline
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Validación; Congelación; Cuestionario; Hombre; Rasagilina
LO :	INIST-20953.354000186090170030
ID :	09-0218140

Links to Exploration step

Pascal:09-0218140

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease</title>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tal, Joseph" sort="Tal, Joseph" uniqKey="Tal J" first="Joseph" last="Tal">Joseph Tal</name>
<affiliation><inist:fA14 i1="02"><s1>TechnoStat Ltd</s1>
<s2>Hod Hasharon</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Azulay, Tali" sort="Azulay, Tali" uniqKey="Azulay T" first="Tali" last="Azulay">Tali Azulay</name>
<affiliation><inist:fA14 i1="02"><s1>TechnoStat Ltd</s1>
<s2>Hod Hasharon</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation><inist:fA14 i1="03"><s1>Service de Pharmacologie Medicale et Clinique, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name>
<affiliation><inist:fA14 i1="06"><s1>Centre of Nervous Diseases, Philipps-University of Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner H. Poewe</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Neuroscience and Neuromed, University La Sapienza</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation><inist:fA14 i1="09"><s1>Neurology Department, Hospital Clinic</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0218140</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0218140 INIST</idno>
<idno type="RBID">Pascal:09-0218140</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F22</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease</title>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tal, Joseph" sort="Tal, Joseph" uniqKey="Tal J" first="Joseph" last="Tal">Joseph Tal</name>
<affiliation><inist:fA14 i1="02"><s1>TechnoStat Ltd</s1>
<s2>Hod Hasharon</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Azulay, Tali" sort="Azulay, Tali" uniqKey="Azulay T" first="Tali" last="Azulay">Tali Azulay</name>
<affiliation><inist:fA14 i1="02"><s1>TechnoStat Ltd</s1>
<s2>Hod Hasharon</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name>
<affiliation><inist:fA14 i1="03"><s1>Service de Pharmacologie Medicale et Clinique, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name>
<affiliation><inist:fA14 i1="06"><s1>Centre of Nervous Diseases, Philipps-University of Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner H. Poewe</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Neuroscience and Neuromed, University La Sapienza</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation><inist:fA14 i1="09"><s1>Neurology Department, Hospital Clinic</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Freezing</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Questionnaire</term>
<term>Rasagiline</term>
<term>Validation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Validation</term>
<term>Congélation</term>
<term>Questionnaire</term>
<term>Homme</term>
<term>Rasagiline</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To revalidate the Freezing of Gait Questionnaire (FOG-Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG-Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ-39). FOG-Q dimensionality, test-retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG-Q with UPDRS, BDI, and PDQ-39. Comparisons between FOG-Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG-Q measures a single dimension. Test-retest reliability and internal reliability of FOG-Q score was high. FOG-Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG-Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as "Freezers" using FOG-Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG-Q was a reliable tool for the assessment of treatment intervention. FOG-Q item 3 was effective as a screening question for the presence of FOG.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GILADI (Nir)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TAL (Joseph)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>AZULAY (Tali)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>RASCOL (Oliver)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BROOKS (David J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MELAMED (Eldad)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>OERTEL (Wolfgang)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>POEWE (Werner H.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>STOCCHI (Fabrizio)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>TOLOSA (Eduardo)</s1>
</fA11>
<fA14 i1="01"><s1>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>TechnoStat Ltd</s1>
<s2>Hod Hasharon</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Service de Pharmacologie Medicale et Clinique, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel-Aviv University</s1>
<s2>Tel-Aviv</s2>
<s3>ISR</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Centre of Nervous Diseases, Philipps-University of Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Neuroscience and Neuromed, University La Sapienza</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Neurology Department, Hospital Clinic</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>655-661</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000186090170030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0218140</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>To revalidate the Freezing of Gait Questionnaire (FOG-Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG-Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ-39). FOG-Q dimensionality, test-retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG-Q with UPDRS, BDI, and PDQ-39. Comparisons between FOG-Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG-Q measures a single dimension. Test-retest reliability and internal reliability of FOG-Q score was high. FOG-Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG-Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as "Freezers" using FOG-Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG-Q was a reliable tool for the assessment of treatment intervention. FOG-Q item 3 was effective as a screening question for the presence of FOG.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Validation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Validation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Validación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Congélation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Freezing</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Congelación</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Questionnaire</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Questionnaire</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cuestionario</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Rasagiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Rasagiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Rasagilina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>159</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0218140 INIST</NO>
<ET>Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease</ET>
<AU>GILADI (Nir); TAL (Joseph); AZULAY (Tali); RASCOL (Oliver); BROOKS (David J.); MELAMED (Eldad); OERTEL (Wolfgang); POEWE (Werner H.); STOCCHI (Fabrizio); TOLOSA (Eduardo)</AU>
<AF>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University/Tel-Aviv/Israël (1 aut.); TechnoStat Ltd/Hod Hasharon/Israël (2 aut., 3 aut.); Service de Pharmacologie Medicale et Clinique, Faculté de Médecine/Toulouse/France (4 aut.); Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital/London/Royaume-Uni (5 aut.); Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel-Aviv University/Tel-Aviv/Israël (6 aut.); Centre of Nervous Diseases, Philipps-University of Marburg/Marburg/Allemagne (7 aut.); Department of Neurology, University of Innsbruck/Innsbruck/Autriche (8 aut.); Department of Neuroscience and Neuromed, University La Sapienza/Rome/Italie (9 aut.); Neurology Department, Hospital Clinic/Barcelona/Espagne (10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 5; Pp. 655-661; Bibl. 24 ref.</SO>
<LA>Anglais</LA>
<EA>To revalidate the Freezing of Gait Questionnaire (FOG-Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG-Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ-39). FOG-Q dimensionality, test-retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG-Q with UPDRS, BDI, and PDQ-39. Comparisons between FOG-Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG-Q measures a single dimension. Test-retest reliability and internal reliability of FOG-Q score was high. FOG-Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG-Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as "Freezers" using FOG-Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG-Q was a reliable tool for the assessment of treatment intervention. FOG-Q item 3 was effective as a screening question for the presence of FOG.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Validation; Congélation; Questionnaire; Homme; Rasagiline</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Validation; Freezing; Questionnaire; Human; Rasagiline</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Validación; Congelación; Cuestionario; Hombre; Rasagilina</SD>
<LO>INIST-20953.354000186090170030</LO>
<ID>09-0218140</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F22 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000F22 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0218140
   |texte=   Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease

Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri